What is PolyCore Therapeutics?
PolyCore Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering treatments for patients afflicted by dyskinesia and cognitive impairment linked to neurodegenerative disorders. The company is currently advancing preclinical investigations for its primary compound, PCT-3012. This novel small molecule is engineered to address Parkinson's motor symptoms and dyskinesia in individuals experiencing early- to mid-stage Parkinson's Disease, positioning PolyCore Therapeutics within the critical sector of neurological therapeutics.
How much funding has PolyCore Therapeutics raised?
PolyCore Therapeutics has raised a total of $4.7M across 1 funding round:
Private Equity
$4.7M
Private Equity (2022): $4.7M, investors not publicly disclosed
What's next for PolyCore Therapeutics?
The substantial enterprise-level investment underscores PolyCore Therapeutics' strategic trajectory towards clinical validation and potential market entry for PCT-3012. This capital infusion is expected to accelerate preclinical studies and prepare the company for subsequent development phases, including potential human trials. The focus on Parkinson's Disease and related cognitive impairments addresses a significant unmet medical need, suggesting a strong market opportunity for effective therapeutic solutions.
See full PolyCore Therapeutics company page
